Page 47 - 《中国药房》2026年1期
P. 47

示,经Esc处理后,HL-60细胞中AKT蛋白的磷酸化水平                           Anticancer  activity  of  Neosetophomone  B  by  targeting
          和SKP2、MTH1蛋白表达水平降低,AKT上游效应信号                            AKT/SKP2/MTH1  axis  in  leukemic  cells[J].  Biochem
          蛋白——p-PI3K 表达水平降低,AKT 下游效应信号蛋                           Biophys Res Commun,2022,601:59-64.
          白——P21、P27 表达水平均升高,表明 Esc 可通过抑制                    [ 9 ]  REN  C,PAN  R  S,HOU  L  S,et  al.  Suppression  of
          AKT/SKP2/MTH1 通路来抑制 AML 细胞的恶性生物学                        CLEC3A inhibits osteosarcoma cell proliferation and pro‐
                                                                  motes  their  chemosensitivity  through  the  AKT1/mTOR/
          行为。同时,本研究在高浓度Esc基础上联合AKT激动
                                                                  HIF1α signaling pathway[J]. Mol Med Rep,2020,21(4):
          剂SC79进一步研究发现,HL-60细胞中以上蛋白的表达
                                                                  1739-1748.
          趋势均发生了逆转,且 Esc 抑制 HL-60 细胞增殖等的生
                                                             [10]  YIN W,FU X,CHANG W W,et al. Antiovarian cancer
          物学活性均受到不同程度的负面影响,这与 Sanjiv 等                 [19]
                                                                  mechanism of esculetin:inducing G0/G1 arrest and apopto‐
          的研究具有相似性。                                               sis via JAK2/STAT3 signaling pathway[J]. J Pharm Phar‐
              综上所述,Esc 可能是通过抑制 AKT/SKP2/MTH1                      macol,2023,75(1):87-97.
          通路,促进HL-60细胞中ROS的大量产生及细胞凋亡程                        [11]  罗祥力,蔡芃夷,唐文 . 秦皮乙素对宫颈癌 SiHa 细胞增
          序的启动,最终抑制 HL-60 细胞增殖。然而,本研究未                            殖、迁移和侵袭的影响及机制[J]. 广西医学,2021,43
          联合其他细胞株或原代细胞进行验证,也未开展动物实                               (20):2430-2435.
          验探讨其体内疗效,后续还需进一步深入研究。                              [12]  马鑫. 秦皮乙素对肾透明细胞癌增殖、周期和凋亡的影
          参考文献                                                    响[J]. 临床泌尿外科杂志,2020,1(11):44-48.
          [ 1 ]  SHIMONY  S,STAHL  M,STONE  R  M. Acute  myeloid   [13]  ZHU P,LI H,GE J,et al. Mechanism of USP11 regulated
              leukemia:2025  update  on  diagnosis,risk-stratification,  SIRT3/ROS in drug resistance of acute myeloid leukemia
              and  management[J].  Am  J  Hematol,2025,100(5):    [J]. Clin Exp Med,2025,25(1):267.
              860-891.                                       [14]  GERMON Z P,SILLAR J R,MANNAN A,et al. Bloc-
          [ 2 ]  SHORT N J,KONOPLEVA M,KADIA T M,et al. Ad‐       kade  of  ROS  production  inhibits  oncogenic  signaling  in
              vances  in  the  treatment  of  acute  myeloid  leukemia:new   acute  myeloid  leukemia  and  amplifies  response  to  preci‐
              drugs  and  new  challenges[J].  Cancer  Discov,2020,10  sion therapies[J]. Sci Signal,2023,16(778):eabp9586.
              (4):506-525.                                   [15]  ZHOU  H  L,ZHOU  L,GUAN  Q,et  al.  SKP2-mediated
          [ 3 ]  BROWN  L  K,KANAGASABAI  T,LI  G  L,et  al.  Co-  MLKL  degradation  confers  cisplatin-resistant  in  non-
              targeting SKP2 and KDM5B inhibits prostate cancer pro‐  small  cell  lung  cancer  cells[J].  Commun  Biol,2023,6
              gression  by  abrogating AKT  signaling  with  induction  of   (1):805.
              senescence  and  apoptosis[J].  Prostate,2024,84(9):  [16]  ZHANG H P,JIANG R Y,ZHU J Y,et al. PI3K/AKT/
              877-887.                                            mTOR signaling pathway:an important driver and thera‐
          [ 4 ]  SHAO Y,REN W L,DAI H,et al. SKP2 contributes to   peutic  target  in  triple-negative  breast  cancer[J].  Breast
              AKT activation by ubiquitination degradation of PHLPP1,  Cancer,2024,31(4):539-551.
              impedes autophagy,and facilitates the survival of thyroid   [17]  KUTTIKRISHNAN  S,AHMAD  F,MATEO  J  M,et  al.
              carcinoma[J]. Mol Cells,2023,46(6):360-373.         Neosetophomone  B  induces  apoptosis  in  multiple
          [ 5 ]  LI C S,XUE Y Y,WU J X,et al. MTH1 inhibition syner‐  myeloma cells via targeting of AKT/SKP2 signaling path‐
              gizes with ROS-inducing agents to trigger cervical cancer   way[J]. Cell Biol Int,2024,48(2):190-200.
              cells  undergoing  parthanatos[J].  Biochim  Biophys  Acta   [18]  KUTTIKRISHNAN S,PRABHU K S,KHAN A Q,et al.
              Mol Basis Dis,2024,1870(5):167190.                  Thiostrepton inhibits growth and induces apoptosis by tar‐
          [ 6 ]  REZOAN HOSSAIN M,ZAHRA SHOVA F T,AKTER           geting  FoxM1/SKP2/MTH1  axis  in  B-precursor  acute
              M,et al. Esculetin unveiled:decoding its anti-tumor poten‐  lymphoblastic leukemia cells[J]. Leuk Lymphoma,2021,
              tial  through  molecular  mechanisms:a  comprehensive  re‐  62(13):3170-3180.
              view[J]. Cancer Rep (Hoboken),2024,7(1):e1948.  [19]  SANJIV K,CALDERÓN-MONTAÑO J M,PHAM T M,
          [ 7 ]  MATHUR A,GANGWAR A,SALUJA  D.  Esculetin  re‐    et  al.  MTH1  inhibitor  TH1579  induces  oxidative  DNA
              leases  maturation  arrest  and  induces  terminal  differentia‐  damage  and  mitotic  arrest  in  acute  myeloid  leukemia[J].
              tion in leukemic blast cells by altering the Wnt signaling   Cancer Res,2021,81(22):5733-5744.
              axes[J]. BMC Cancer,2023,23(1):387.                           (收稿日期:2025-09-17  修回日期:2025-12-17)
          [ 8 ]  KUTTIKRISHNAN  S,BHAT A A,MATEO  J  M,et  al.                                    (编辑:林 静)





          中国药房  2026年第37卷第1期                                                  China Pharmacy  2026 Vol. 37  No. 1    · 41 ·
   42   43   44   45   46   47   48   49   50   51   52